Navigation Links
Immuno-Oncology 360° Summit Confirms Program Line-up for February 7-9, 2018
Date:8/28/2017

The Conference Forum has announced the program line-up for the 4th annual Immuno-Oncology 360° event, which will take place on February 7-9, 2018 in New York, NY.

Designed by lead advisors Axel Hoos, MD, PhD, SVP of Oncology R&D at GlaxoSmithKline, and James Gulley, MD, PhD, Head of Immunotherapy Section and Director of Medical Oncology Service at the Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, more than 30 speakers cover the full spectrum of IO research and development, from translational and clinical to emerging technologies, business aspects, investor relations and trends in the field.

“Now in its fourth year, IO360° continues to help the immuno-oncology community stay at the forefront of the most relevant research and developments from key industry leaders, who have their fingers on the pulse of cancer immunotherapy,” says IO360° conference director Kate Woda. “Through a series of plenary sessions, the summit helps to foster collaboration between the different parties working in all aspects of cancer immunotherapy so that they can better understand what assets are available for potential combinations that may provide patients with more treatment options.”

Day One of 2018’s event starts with the Discovery & Preclinical Plenary Session, which includes presentations on NK Cell CARs; target discovery for CAR-Ts and TCRs; combination IDO1 and PD-1 inhibition in metastatic melanoma; and the early clinical data on dual targeting of PDL1 and TGF Beta. The Investor Relations in Immunotherapy Plenary Session starts with a keynote evaluating and forecasting the IO Space given by Andrew Baum, MD, Head of Global Healthcare and Managing Director of Equity Research at Citi, then continues with a venture capitalist perspective on the IO Landscape, and an investor roundtable on the role of IO within large pharma moderated by Axel Hoos. Concluding the day is the Translational Science and Biomarkers Plenary Session with sessions on: the role of anitbody isotypes for agonist antibodies; tumor mutation burden; immune suppression in the tumor micro-environment; the MORPHEUS Novel CIT Platform to address multiple combinations; cancer vaccinations and biomarkers of response; using TC Clonality for detecting minimal residual disease; the use of imaging biomarkers for immunotherapy; neoantigen approaches for biomarkers; and emerging concepts for detecting minimal residual disease using liquid biopsies.

Day Two begins with the New Trends & Collaboration Plenary Session. Presentations include a BioCentury report on industry trends, a bulletin from Endpoint News, an update on the Cancer Moonshot, information on immuno-oncology progress in China, and a talk on Clinical Trial Collaborations in IO. The IO Emerging Technologies & Innovative Solutions Plenary Session showcases companies with technologies and solutions that will help IO stakeholders advance developments to provide treatment for cancer patients. The day ends with a choice between two concurrent tracks. The first track is the Business Aspects Plenary Session, which covers a summary of IO deals; a large pharma perspective on IO licensing technology; and finally a panel on talent management for IO. As immuno-oncology clinical trials have exceptionally unique requirements, the second track is the new Clinical Operations for IO Trials Plenary Session, featuring a specialized section on the building blocks of clinical trial design and operations.

Day Three opens with the Clinical Aspects Plenary Session. Topics covered include: balancing benefit and toxicity from immunotherapeutics and how to make recommendations to patients; maintenance therapy in NSCLC; Keytruda in combination with chemo in NSCLC; an update on Tecentriq (Atezolizumab) in bladder cancer; the changing treatment landscape in NSCLC; Pembrolizumab as a broad spectrum anticancer therapy both as mono and combination therapy; and the differences in long term benefit between classes of checkpoint modulators. The summit concludes with the Trout Group Situation Room. The session includes a presentation on the investor lifecycle and how to maneuver at each stage of financing from seed to public market; CEO Panel: Raising Money in the Current Climate; and fireside chats with IO CEOs.

Find out more about IO360°.

About the Conference Forum
The Conference Forum is a research firm that develops specialized events for professionals in the life science and healthcare industries. The company currently offers conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists, patient advocates and non-profit/government healthcare groups. The Conference Forum’s mission is to create the best content, facilitate the exchange ideas and provide quality networking to help move therapeutics to patients faster.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14634993.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma
2. ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting
3. Heptares and AstraZeneca Enter Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers
4. FDA Grants Orphan Drug Designation for Tocagens Toca 511 & Toca FC, an Investigational Immuno-Oncology Treatment for Glioblastoma
5. Infinity to Provide Update on Duvelisib and Immuno-Oncology Development Candidate IPI-549 During 2015 Research and Development Day
6. F-star Enters Into Collaborative Discovery & Development Agreement With AbbVie for Bispecific Antibodies in Immuno-oncology
7. Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan
8. HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University
9. PharmaVentures Advises 3Legs Resources on its Acquisition of the Immuno-Oncology Company SalvaRx Who Announced its Admission for Trading on AIM Today
10. F-star Selects Genedata Biologics for Immuno-Oncology Therapeutics Discovery
11. Immuno-Oncology: A 360° View in NYC this February
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2018)... (PRWEB) , ... July 25, 2018 , ... ... vivo research utilizing its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate ... to Chief Scientific Officer. Additionally, the company announced the appointment of Jeff Caron ...
(Date:7/25/2018)... ... July 25, 2018 , ... Almac Clinical ... and supplies data through its flagship IXRS® 3 Interactive Response Technology (IRT) ... This podcast features both Almac thought leaders and outside experts discussing best practices ...
(Date:7/24/2018)... OMAHA, Neb. (PRWEB) , ... July 23, 2018 ... ... the impact of a biofield energy treated nutraceutical to increase immunity and improve ... well as, immune function response assessed in the preclinical research were significantly reduced. ...
(Date:7/24/2018)... ... , ... Boval was founded in 1978 when Mr. Douglas Northcott began making ... days most of the BSA manufactured was for blood banking reagents; however, in the ... cards changed that market and displaced most of the large volume needs. Boval ...
Breaking Biology Technology:
(Date:8/1/2018)... (PRWEB) , ... August 01, 2018 , ... Dr. Asher ... announced the winning recipients of the 2018 IAC Awards at the 23rd World Congress ... the committee also named four faculty to receive the Distinguished Fellowship Awards. , Dr. ...
(Date:7/31/2018)... ... , ... ACEA Biosciences, is a privately owned biotechnology company which develops cutting ... RTCA S16, which the ideal entry level model for exploratory studies in cell biology. ... in any standard CO2 tissue culture incubator. The user friendly RTCA software allows ...
(Date:7/29/2018)... , ... July 29, 2018 , ... Dr. William Plikerd, ... energy treated nutraceutical to improve overall immunity and to combat inflammation and autoimmune disorders. ... as inflammation. The following data was reported:, Up to ...
Breaking Biology News(10 mins):